Other Barks & Bites for Friday, February 4: CRISPR Gene Editing Tech Debated at PTAB, PhRMA Calls Out 'Deeply Concerning' TRIPS Waiver to USTR, Deadline Closes for Comments on SEP Draft Policy Statement IPWatchdog.com
